US Codex
C.F.R.
Browse by date
Notes

§320.22. Criteria for waiver of evidence of in vivo bioavailability or bioequivalence. — Inbound Citations

21 C.F.R. § 320.22

Cited by 4 regulations in release Current.

Citations to 21 C.F.R. § 320.22 as a whole

Citations to §320.22(d)(2)(i)

  • (2) The drug product is in the same dosage form, but in a different strength, and is proportionally similar in its active and inactive ingredients to another drug product for which the same manufacturer has obtained approval and the conditions in paragraphs (d)(2)(i) through (d)(2)(iii) of this section are met:
    (i) The bioavailability of this other drug product has been measured;
    (ii) Both drug products meet an appropriate in vitro test approved by FDA; and
    (iii) The applicant submits evidence showing that both drug products are proportionally similar in their active and inactive ingredients.

Citations to §320.22(d)(2)(ii)

  • (2) The drug product is in the same dosage form, but in a different strength, and is proportionally similar in its active and inactive ingredients to another drug product for which the same manufacturer has obtained approval and the conditions in paragraphs (d)(2)(i) through (d)(2)(iii) of this section are met:
    (i) The bioavailability of this other drug product has been measured;
    (ii) Both drug products meet an appropriate in vitro test approved by FDA; and
    (iii) The applicant submits evidence showing that both drug products are proportionally similar in their active and inactive ingredients.

Citations to §320.22(d)(2)(iii)

  • (2) The drug product is in the same dosage form, but in a different strength, and is proportionally similar in its active and inactive ingredients to another drug product for which the same manufacturer has obtained approval and the conditions in paragraphs (d)(2)(i) through (d)(2)(iii) of this section are met:
    (i) The bioavailability of this other drug product has been measured;
    (ii) Both drug products meet an appropriate in vitro test approved by FDA; and
    (iii) The applicant submits evidence showing that both drug products are proportionally similar in their active and inactive ingredients.